Unknown PHASE2 INTERVENTIONAL 2-arm NCT04148898

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (OWONBNSCLCLM)

A Randomized Phase II Trial of Osimertinib Alone or in Combination With Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Sponsor: Nanchang University

Conditions EGFR Activating Mutation Leptomeningeal Metastasis Non-small Cell Lung Cancer

Interventions Bevacizumab Osimertinib

Updated 5 times since 2019 Last updated: Nov 1, 2019 Started: Nov 1, 2019 Primary completion: Mar 1, 2021 Completion: Jul 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates EGFR Activating Mutation and Leptomeningeal Metastasis and is currently ongoing. Nanchang University leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2
Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanchang University
Second Affiliated Hospital of Nanchang University

Data source: Second Affiliated Hospital of Nanchang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.